The ACR will be working with the Senate as they consider and debate the important healthcare policies contained in this massive legislation.

Anti-SAE Identifies a Subtype of Dermatomyositis
Albayda et al. describes a North American cohort of patients with dermatomyositis, reporting that small ubiquitin-like modifier activating enzyme (SAE) autoantibodies are clearly associated with this clinical disease. Patients with this clinical phenotype most commonly present with a rash first, followed by muscle involvement.

Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy
A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.
Extreme & Uncontrollable Circumstances Policy Will Apply to All MIPS-Eligible Clinicians 2021
The final rule, issued Nov. 2, finalizes many proposed policies, including a decreased conversion factor, billing for shared visits and teaching services, continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.
ACR Overview of 2022 Medicare Physician Fee Schedule Final Rule
The final rule, issued Nov. 2, finalizes many policies in the July proposed rule, including the decreased conversion factor, billing for shared visits and teaching services, the continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.

Policy Change Made Reality in 2021
After a year marked with rheumatology gains in evaluation and management valuation, as well as quality reporting, ongoing ACR efforts target impending Medicare reimbursement cuts and other practice challenges.

Howard Blumstein, MD, Assumes RheumPAC Chair
“Advocacy is not about bribery. There’s nothing dirty about advocating for your patients and the future of your profession in terms of workforce, therapeutic advances and the financial viability of our practices. It’s our duty to do this,” he says. In his new role as the RheumPAC chair, he wants to help ACR/ARP members “see how vital these activities are to the success of our profession.”

Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis
Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.

ACR-Led Resolutions at AMA House of Delegates Meeting Protect Rheumatology Practices, Patient Access
If passed, the ACR-led resolutions will direct the AMA to advocate for state-level pharmacy benefit manager reform and to fix broken Medicare Administrator Contractor processes. Several other specialties joined the ACR’s resolutions as supporting cosponsors.
The Relative Value Update Process: Your Input Makes a Difference
Selected ACR members will be invited to participate in a survey from the AMA Relative Value Update Committee. If you do, respond by the listed date. Data from these surveys helps set Medicare and other payer reimbursement rates.
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 325
- Next Page »